Anzeige
Mehr »
Samstag, 05.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
424 Leser
Artikel bewerten:
(2)

FUJIFILM Europe GmbH: FUJIFILM Europe launches new software for SCALE EYE¹, a real-time virtual scale function to aid endoscopists in estimating the size of lesions in the colon

The virtual scale is integrated within the endoscopic field of view.

The virtual scale was designed to support endoscopists estimate the size of lesions.

RATINGEN, Germany, Oct. 06, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Europe GmbH has launched the new software EW10-VM01 for SCALE EYE real-time virtual scale function ("SCALE EYE"), designed to help endoscopists estimate the size of lesions in the colon. SCALE EYE is the latest technology to be launched as part of the ELUXEO Ultra platform, delivering a comprehensive package for endoscopists.

Endoscopists are facing increased demand due to the growing incidence of colorectal cancer across Europe. Colorectal cancer accounted for 12.7% of all new cancer diagnoses in Europe in 2020, making it the second most frequently occurring cancer.2 Early detection and diagnosis of cancer and pre-cancerous lesions have been proven to significantly reduce the complexity of treatment and improve patients' outcomes.3

When deciding on therapeutic intervention within the colon, such as resect and discard, EMR, and ESD, lesion size is considered one of the important factors.4 However, it is not always straightforward to estimate lesion size in the endoscopic field of view.

Fujifilm has developed SCALE EYE, a function designed to aid endoscopists in estimating the size of lesions in the colon. By simply pressing the endoscope switch, SCALE EYE is activated to support the endoscopist to determine the size of the lesion within the endoscopic field of view.

How SCALE EYE works
The SCALE EYE system includes the newly developed endoscope EC-760S-A/M, L, which is equipped with a class 1 laser. The laser point is visible within the endoscopic image. The position of the laser point changes relative to the distance between the tip of endoscope and the object. Depending on this laser point position, the scale interval size adjusts automatically.

The laser point needs to be positioned on the left hand side of the lesion and the virtual scale will be displayed on the right hand side.

User interface
Scale size is selectable from 5mm, 10mm, and 20mm, and the activation and the deactivation of the function can be simply operated by the endoscope switch.

The virtual scale is displayed on the same endoscopic monitor in real-time and does not require a separate monitor.

The software for SCALE EYE (EW10-VM01) can be installed in the expansion unit EX-1, which can also be used to utilize CAD EYE5 Detection and Characterization.

Saskia Papa, Senior Product Manager at FUJIFILM Europe GmbH said:
"SCALE EYE is yet another technological leap forward in the fight against colorectal cancer by targeting challenges faced by colonoscopists. It is widely known that whilst detection and accurate characterization of lesions has an impact on the occurrence of interval cancers, accurate measurement of lesions is vital in not only assigning appropriate surveillance intervals but also to determine the most appropriate course of therapy. With SCALE EYE, we have a real chance to further support physicians in improving the quality of colonoscopy, from screening through to treatment and to ultimately improve the lives of patients."

About Fujifilm in Europe

Fujifilm operates over 50 group companies and branches in Europe and employs more than 6000 people engaged in R&D, manufacturing, sales and service, with FUJIFILM Europe GmbH, located in Ratingen, Germany, operating as the strategic headquarters for the region. Throughout Europe, Fujifilm entities serve a range of industries including medical technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage and all aspects of photography. Over the last 20 years, the company has more intensively focused on healthcare - from diagnosis to prevention and treatment. Today, Fujifilm in Europe provides the entire spectrum of patient care, in addition to research, development and manufacturing in advanced therapies, gene therapies and vaccines, as well as providing cell culture media and regenerative medicine solutions.
For more information, please visit: fujifilm.com

About ELUXEO Ultra

Fujifilm's Eluxeo Ultra system is one of the first endoscopy platforms to detect and characterize lesions in real-time. It enhances Fujifilm's existing ELUXEO system by incorporating SCALE EYE, a real-time virtual scale function designed to aid endoscopists in estimating the size of lesions in the colon, and ColoAssist PRO, our real-time endoscope visualisation system to deliver a comprehensive package for endoscopists. These are the latest additions to the ELUXEO Ultra family of endoscopy technologies, which follow the launch of CAD EYE, a colon polyp detection and characterisation function utilising AI technology. The ELUXEO Ultra platform will accommodate a range of future tools and technologies as they evolve, so Fujifilm's best endoscopy system for patients today, will remain so tomorrow.


1 SCALE EYE is a Fujifilm brand name of function to support size estimation by virtual scale. To enable SCALE EYE, the EC-760S-A/M and EC-760S-A/L colonoscopes which are equipped with a red laser are used in combination with the "Endoscopy Support Program EW10-VM01."
2 Colorectal cancer burden in EU-27, European Commission. 2021. https://ecis.jrc.ec.europa.eu/pdf/Colorectal_cancer_factsheet-Mar_2021.pdf
3 World Cancer Day 2019: Emphasis on Early Detection. 2019. https://ascopost.com/News/59711
4 Colorectal polypectomy and endoscopic mucosal resection5 CAD EYE is a Fujifilm brand name of function to assist computer-aided-diagnosis (CAD) in endoscopy. The function was designed with Deep Learning, which is a form of Artificial Intelligence technology, and does not automatically change system performance or accuracy once installed. CAD EYE can be used by installing "Endoscopy Support Program EW10-EC02" on the expansion unit EX-1.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a38da3-7222-41e7-b21e-845aec277762

https://www.globenewswire.com/NewsRoom/AttachmentNg/cd1aa0a6-e71d-4032-9e98-4cdfcdd367da

https://www.globenewswire.com/NewsRoom/AttachmentNg/3bef7a1b-f1c7-458a-bc7b-3a892a698b82

Nina Strupeit
Marketing Specialist
Endoscopy Systems European Medical Systems Division
E-mail: nina.strupeit@fujifilm.com


© 2022 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.